Physician profile
Angela Thomas
NPI 1427474600
$8,438.95
in general payments reported to CMS, 2019-2025
26 companies · $2,480 in 2025
The $2,480 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $1,826 · 2023: $2,002 · 2024: $1,653 · 2025: $2,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,134.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,641.27 | 2021-2025 | |
| Madrigal Pharmaceuticals | $874.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $842.98 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $601.05 | 2021-2025 | Entyvio, Gattex |
| Celgene Corporation | $584.87 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $465.91 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.81 | 2022-2023 | Xifaxan, Trulance |
| Ardelyx, INC. | $384.47 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $267.59 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $245.65 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $228.42 | 2021-2025 | Ocaliva |
| Genzyme Corporation | $125.81 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $120.89 | 2023 | Zeposia |
| Pfizer INC. | $111.55 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $94.83 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $79.09 | 2023-2024 | Hadlima |
| Regeneron Healthcare Solutions, INC. | $67.49 | 2023-2024 | Dupixent |
| Gilead Sciences, INC. | $58.95 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $52.38 | 2022-2024 | Dificid |
| Braintree Laboratories, INC. | $47.83 | 2022-2023 | Sutab |
| Albireo Pharma, INC. | $25.72 | 2024 | Iqirvo |
| Redhill Biopharma INC. | $23.15 | 2022 | |
| Qol Medical, LLC | $22.29 | 2023 | Sucraid |
| Phathom Pharmaceuticals, INC. | $22.16 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $19.97 | 2023 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $17.30 | 2023 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.